Home › Agent Hub › Agent Tools › Part D coverage by drug › Namzaric
Agent Tools
Namzaric is a brand of donepezil / memantine. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 2,096 of 5,496 Medicare Part D and Medicare Advantage drug plans (38.1%) list Namzaric on their formulary, across 113 of 328 formularies. The most common placement is tier 4 (1,389 plans, 66.3% of those covering it). 23 of the covering plans require prior authorization (1.1%), 49 step therapy and 69 a quantity limit.
131 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $42, 33 of them $0; 1,965 charge coinsurance instead — median 25% of the drug's cost. Once a member's out-of-pocket drug spending reaches $2,100 in 2026, covered drugs cost $0 for the rest of the year.
2025: 4,506 of 5,631 plans covered it (80%); 2026: 2,096 of 5,496 (38.1%).
Of 4,368 plans offered in both years, 8 added it to the formulary and 1,912 dropped it.
Among plans covering it both years, 88 moved it to a higher tier and 7 to a lower one; 0 added prior authorization and 13 removed it.
Medicare Part D paid for 175,650 30-day fills of Namzaric in 2024 for about 18,215 enrollees, at an average total cost of $510.04 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Namzaric and the rest of a client's list on every plan in their county.
Estimate Namzaric costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.